TPG has acquired a minority stake in Sai Life Sciences (Sai), a pharma firm. TPG Capital Asia acquired the equity stake from Tata Capital. Financial terms of the transaction were not disclosed.
Headquartered in Hyderabad, Sai is an integrated provider of drug discovery, development, and manufacturing solutions for innovator pharmaceutical and biotechnology companies.
Currently serving seven out of the top 15 global pharmaceutical companies, Sai is well-positioned to facilitate the launch of 25 new medicines by global innovator partners through 2025, said Krishna Kanumuri, CEO of Sai.
“In recent years, contract development and manufacturing companies (CDMOs) have started to gain